Last reviewed · How we verify
NCT06862700: VREM-CS
Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients
trial testing Vasopressor Exposure Levels in Cardiogenic Shock in 534 participants. Currently enrolling.
1 January 2027
Quick facts
| Lead sponsor | Xiaotong Hou |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 534 |
| Start date | 26 February 2025 |
| Primary completion | 1 January 2027 |
| Estimated completion | 1 January 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Vasopressor Exposure Levels
Conditions studied
- Cardiogenic Shock — all drugs for Cardiogenic Shock →
- Extracorporeal Membrane Oxygenation — all drugs for Extracorporeal Membrane Oxygenation →
- Vasopressors — all drugs for Vasopressors →
- Hemodynamic Management — all drugs for Hemodynamic Management →
Sponsor
Xiaotong Hou — full company profile →
Who can join
18 and older, any sex, with Cardiogenic Shock or Extracorporeal Membrane Oxygenation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to learn about the association between vasopressor exposure levels and outcomes in adults with cardiogenic shock receiving VA-ECMO. The main question it aims to answer is: Does reduced exposure to vasopressors lower the 30-day mortality in patients with cardiogenic shock when receiving ECMO support? Participants who are receiving ECMO support for cardiogenic shock as part of their regular medical care will have their data collected, including information about their vasopressor use and mortality outcomes, over the course of the study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06862700
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiogenic Shock
Currently open trials in the same condition.
- NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
- NCT07345559 — Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic Shock · NA · recruiting
- NCT07374289 — On Scene ECPR in Ostrava · NA · recruiting
- NCT07402018 — Intra-aortic Balloon Counterpulsation (IABC) Compliance · recruiting
- NCT07309029 — Pre-Emptive LAVA-ECMO for Complex High-Risk TAVR · recruiting
Other Xiaotong Hou trials
Trials by the same sponsor.
- NCT06276010 — Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO · NA · recruiting
- NCT06275555 — Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06862700 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xiaotong Hou
- Last refreshed: 6 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06862700.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing